chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Swelling face
Clinical narrative: Swelling of face / left jaw area; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8737) via an unspecified route of administration in the left arm on 13Apr2021 at 09:30 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies. Concomitant medications included venlafaxine (MANUFACTURER UNKNOWN) and esomeprazole magnesium dihydrate (MANUFACTURER UNKNOWN); taken for unknown indications from an unknown date and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 18:30, the patient experienced swelling of face / left jaw area. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. The clinical outcome of the event swelling of face / left jaw area was recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Myalgia, Nausea, Vomiting
Clinical narrative: About 12 hours after injection, I woke up with nausea; About 12 hours after injection, I woke up with vomitting; About 12 hours after injection, I woke up with chills; Headache; Muscle soreness; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the left arm on 14Apr2021 at 12:00 (at the age of 63-year-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high/taking meds for this. The patient had no known allergies to medications, food and other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included metoprolol (MANUFACTURER UNKNOWN) and clonidine (MANUFACTURER UNKNOWN), both from unknown dates for unknown indications. The patient previously received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 24Mar2021 at 12:15 (at the age of 63-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15Apr2021 at 00:00, the patient experienced woke up with nausea and vomiting, chills, headache and sore muscles. This lasted the better part of night with headache and sore muscles lasting longer. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events nausea and vomiting, chills resolved on an unknown date in Apr 2021; while that of the events headache and sore muscles recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Chills, Epistaxis, Headache, Myalgia
Clinical narrative: Body aches; Nose bleed; Weak; Muscle aches; Chills (no fever); Headache; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old, non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER 8729) via an unspecified route on 12Apr2021 at 17:30 in the left arm (at an age of 58-year-old) as single dose for COVID-19 immunisation. The medical history of the patient included hypothyroidism. The patient did not have any allergies to medications, food, or other products. Concomitant medications were not reported. The patient received other vaccination within 4 weeks prior to the COVID vaccine. Previously, the patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER 8727) via an unspecified route on 22Mar2021 in the left arm as single dose for COVID-19 immunisation.  Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 13Apr2021 at 03:00, the patient experienced headache, chills (no fever), body/muscle aches, weak and nose bleed. Therapeutic measures were not taken as a result of the event. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events of headache, chills (no fever), body/muscle aches, weak and nose bleed was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: Body aches; Nose bleed; Weak; Muscle aches; Chills (no fever); Headache; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old, non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER 8729) via an unspecified route on 12Apr2021 at 17:30 in the left arm (at an age of 58-year-old) as single dose for COVID-19 immunisation. The medical history of the patient included hypothyroidism. The patient did not have any allergies to medications, food, or other products. Concomitant medications were not reported. The patient received other vaccination within 4 weeks prior to the COVID vaccine. Previously, the patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER 8727) via an unspecified route on 22Mar2021 in the left arm as single dose for COVID-19 immunisation.  Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 13Apr2021 at 03:00, the patient experienced headache, chills (no fever), body/muscle aches, weak and nose bleed. Therapeutic measures were not taken as a result of the event. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events of headache, chills (no fever), body/muscle aches, weak and nose bleed was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Nausea, Pain, Pain in extremity, Vaccination site pain
Clinical narrative: Soreness / tenderness in left arm (injection arm)when parallel to ground,; Achiness; Increased nausea; Soreness at the injection site; Increased fatigue throughout the day.; This is a spontaneous report from a contactable other healthcare professional, the patient. A 32-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200) via an unspecified route of administration in the left arm on 10Apr2021 at 10:30 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. Medical history included GERD, herpes simplex 1, 2, allergy to dust mites and mold (spores). Concomitant medications included omeprazole (MANUFACTURER UNKNOWN) 20mg daily for unknown indication from an unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 13Mar2021 at 10:30 (at the age of 31-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 the day of dose 2 at 14:00, the patient experienced soreness at the injection site with increased fatigue throughout the day and took 1,000mg of tylenol extra strength before bed. On the day after dose 2, on 11Mar2021, the patient experienced soreness/tenderness in left arm the injection arm when parallel to ground, increased fatigue/achiness and increased nausea and took 1,000 mg of tylenol extra strength when woke up, and another 1,000mg of tylenol in the afternoon. By day two on 12Apr2021, all symptoms resolved. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of events and included treatment with acetaminophen (TYLENOL) extra strength 1000mg on 10Apr2021 and 11Apr2021. The clinical outcome of the event soreness at the injection site, increased fatigue, Soreness /tenderness in left arm (injection arm) when parallel to ground, increased fatigue / achiness and increased nausea were recovered on 12Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Nausea, Pain, Pyrexia
Clinical narrative: body ache; headache; fever; nausea; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 13Apr2021 at 13:30 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included Tumor involves more than half of a lobe, but not both lobes (T2B) and High Blood Pressure (HBP). Concomitant medications included dulaglutide (TRULICITY), amlodipine (MANUFACTURER UNKNOWN), acetylsalicylic acid (ASPIRIN), metoprolol (MANUFACTURER UNKNOWN) and atorvastatin calcium (LIPITOR), all taken for unspecified indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 23Mar2021 at 13:30 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15Apr2021 at 03:30, the patient experienced body ache, headache, fever and nausea. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events body ache, headache, fever and nausea were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Headache, Myalgia, Pyrexia, Vaccination site pain
Clinical narrative: Fever; Chills; Headache; Muscle aches; Injection site soreness; This is a spontaneous report from a contactable consumer, the patient. A 17-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 14Apr2021 at 12:30 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. Other medical history was reported as none. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 24Mar2021 at 12:30 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15Apr2021 at 07:00, the patient experienced fever, chills, headache, muscle aches and injection site soreness. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills, headache, muscle aches and injection site soreness were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Increased appetite, Urticaria, Vaccination site pain
Clinical narrative: Pain at vaccination site; Singular hive on cheek; Increased appetite; Fatigue; This is a spontaneous report from a contactable consumer. A female patient of unknown age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13Apr2021, as a single dose for COVID-19 immunisation. Medical history was reported as none. Concomitant medications were not reported. The patient had no known allergies. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on unknown location, as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021, the patient experienced pain at vaccination site, singular hive on cheek, increased appetite and fatigue. Therapeutic measures were not taken as a result of these events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events pain at vaccination site, singular hive on cheek, increased appetite and fatigue was recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Asthma, Dyspnoea, Feeling cold, Headache, Tremor
Clinical narrative: I got severe headache; difficult breathing; chilling; shaking symptoms after 20 hours I was vaccinated; I have asthma background; This is a spontaneous report from a contactable consumer (patient) or other non hcp. A 58-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot number was not reported and expiry date: unknown), dose 1 via an unspecified route of administration, administered in Arm Left on 13Apr2021 at 12:15 as DOSE 1, SINGLE for covid-19 immunisation. Medical history included tuberculosis (TB background), asthma (Having asthma). The patient had no known allergies. The patient's concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. The patient experienced I got severe headache, difficult breathing, chilling, shaking symptoms after 20 hours I was vaccinated and I have asthma background on 14Apr2021 at 07:30. No treatment was received for the events. Outcome of all the events was recovering.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained.
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: Migraine
Clinical narrative: Extremely painful migraine on left side temple; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the arm left on 14Apr2021 at 19:30 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not receive any concomitant medications within two weeks of the COVID vaccine. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the arm left on 24Mar2021 at 12:30 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 15Apr2021 at 08:00, the patient experienced extremely painful migraine on left side temple. No therapeutic measures were taken as a result of these events. The clinical outcome of the event migraine was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Vomiting
Clinical narrative: Body chills and violent vomiting for 4 hours; Body chills and violent vomiting for 4 hours; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 12Apr2021 at 14:15 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. The patient had no other medical history and no known allergies to medications, food, or other products. Concomitant medication taken within two weeks of vaccination included prenatal vitamins for unknown indication from unknown date. The patient previously took the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 22Mar2021 at 14:15 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 at 02:00, the patient experienced body chills and violent vomiting for four hours. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events body chills and violent vomiting for four hours was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Extreme headache daily since first dose of vaccine, two weeks ago today.; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 01Apr2021 at 14:45 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history.  The patient did not receive any medication within two weeks of vaccination. The patient had no known allergies to medications, food and other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021 at 16:00, the patient experienced extreme headache daily since first dose of vaccine, two weeks ago today. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. . The patient did not receive any treatment for the reported event. The clinical outcome of the event extreme headache was not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Feeling abnormal, Gastric disorder, Oropharyngeal pain, Rhinorrhoea
Clinical narrative: Dizziness (motion sickness like); Drowsiness; Runny nose; loose stomach (no diarrhoea yet); sore, scratchy throat (similar to Strep Throat); sore, scratchy throat (similar to Strep Throat); Fogginess (unable to process information rapidly); This is a spontaneous report from a contactable consumer, the patient. A 28-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO164) via an unspecified route of administration in the left arm on 14Apr2021 at 12:00 (at the age of 28-years-old), as a single dose for COVID-19 immunisation. Medical history reported as none. Concomitant medications were reported as not applicable. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The known allergies to medications, food, or other products were reported as none. On 14Apr2021 at 14:00, the patient experienced dizziness (motion sickness like), drowsiness, runny nose, loose stomach (no diarrhea till the time of reporting), sore, scratchy throat (similar to strep throat) and fogginess (unable to process information rapidly).  The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events dizziness (motion sickness like), drowsiness, runny nose, loose stomach (no diarrhea till the time of reporting), sore, scratchy throat (similar to strep throat) and fogginess (unable to process information rapidly) was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Somnolence, Throat irritation
Clinical narrative: Dizziness (motion sickness like); Drowsiness; Runny nose; loose stomach (no diarrhoea yet); sore, scratchy throat (similar to Strep Throat); sore, scratchy throat (similar to Strep Throat); Fogginess (unable to process information rapidly); This is a spontaneous report from a contactable consumer, the patient. A 28-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO164) via an unspecified route of administration in the left arm on 14Apr2021 at 12:00 (at the age of 28-years-old), as a single dose for COVID-19 immunisation. Medical history reported as none. Concomitant medications were reported as not applicable. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The known allergies to medications, food, or other products were reported as none. On 14Apr2021 at 14:00, the patient experienced dizziness (motion sickness like), drowsiness, runny nose, loose stomach (no diarrhea till the time of reporting), sore, scratchy throat (similar to strep throat) and fogginess (unable to process information rapidly).  The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events dizziness (motion sickness like), drowsiness, runny nose, loose stomach (no diarrhea till the time of reporting), sore, scratchy throat (similar to strep throat) and fogginess (unable to process information rapidly) was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus- ringing in right ear.; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old, non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6203) via an unspecified route on 27Feb2021 at 10:30 hours in the left arm (at the age of 65-years-old) as single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. The medical history of the patient included high blood pressure and shellfish allergy (clams). The patient previously received Claritin (MANUFACTURER UNKNOWN) started on an unknown date for an unknown indication and experienced drug allergy. The patient received other medications (unspecified) within 2 weeks of the COVID-19 vaccine. The patient did not receive other vaccination within 4 weeks prior to the COVID vaccine. Previously, the patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EM9809) via an unspecified route on 06Feb2021 at 10:30 hours in the right arm as single dose for COVID-19 immunisation. Since the vaccination, the patient was not tested for COVID-19. On 01Mar2021, the patient experienced tinnitus- ringing in right ear. No therapeutic measures were taken as a result of the  reported event. The event resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the event of tinnitus- ringing in right ear was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Feeling abnormal, Headache, Insomnia
Clinical narrative: Inability to sleep; Fatigue; Headache; brain fog; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 3248) via an unspecified route of administration in the right arm on 13Apr2021 at 11:30 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. The patient had no known allergies. Concomitant medications included hydrochlorothiazide (MANUFACTURER UNKNOWN) and amlodipine besylate (MANUFACTURER UNKNOWN), both taken for unspecified indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 3248) via an unspecified route of administration in the right arm on 23Mar2021 at 11:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 03:00, the patient experienced inability to sleep, fatigue, headache and brain fog. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events inability to sleep, fatigue, headache and brain fog were resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Ageusia
Clinical narrative: Lost sense of taste; This is a spontaneous report from a contactable consumer, the patient. A non-pregnant, female patient of unknown age received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route on 09Apr2021 at 09:45 as single dose for COVID-19 immunisation. Prior to vaccination, it was unknown if the patient was diagnosed with COVID-19. The medical history and concomitant therapy were not reported. It was unknown if the patient received any other medication within 2 weeks of COVID vaccination. It was unknown if the patient received other vaccination within 4 weeks prior to the COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) on an unknown date as single dose for COVID-19 immunisation. Since the vaccination, it was unknown if the patient was tested for COVID-19. On 09Apr2021, Friday night, the patient had lost sense of taste. The taste returned on 10Apr2021, Saturday, with some foods but not others - intermittent. It was better on Sunday. Therapeutic measures were not taken as a result of the event. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event of lost sense of taste was recovered on an unknown date in Apr2021.   No follow-up attempts are possible; information about lot number cannot be obtained. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Anxiety, Dizziness, Glycosylated haemoglobin, Headache, Heart rate
Clinical narrative: Dizzy; Headache; Lots of anxiety; Elevated heart rate; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 29Mar2021 at 10:00 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history included type 1 diabetes mellitus, hashimoto's disease, depression and anxiety. The patient received unspecified medication within two weeks of vaccination. The patient had no allergies to medications, food, or other products. The patient previously took the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the right arm on 07Mar2021 at 15:00 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 07:00, It had been 2 weeks passed her second shot. She had no affects after the first or second shot immediately after. But now, the patient experienced dizzy, headache (small), lots of anxiety, elevated heart rate. She was type 1 diabetic in good control (5.5 A1C). The evets resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were taken as a result of reported events and included treatment with hydration. On an unknown date, the patient underwent HbA1C and the result was 5.5. On 14Apr2021, the patient underwent nasal swab rapid test and the result was negative and heart rate and the result was elevated. The clinical outcome of the events dizzy, headache (small), lots of anxiety and elevated heart rate were not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Heart rate increased, SARS-CoV-2 test
Clinical narrative: Dizzy; Headache; Lots of anxiety; Elevated heart rate; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 29Mar2021 at 10:00 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history included type 1 diabetes mellitus, hashimoto's disease, depression and anxiety. The patient received unspecified medication within two weeks of vaccination. The patient had no allergies to medications, food, or other products. The patient previously took the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the right arm on 07Mar2021 at 15:00 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 07:00, It had been 2 weeks passed her second shot. She had no affects after the first or second shot immediately after. But now, the patient experienced dizzy, headache (small), lots of anxiety, elevated heart rate. She was type 1 diabetic in good control (5.5 A1C). The evets resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were taken as a result of reported events and included treatment with hydration. On an unknown date, the patient underwent HbA1C and the result was 5.5. On 14Apr2021, the patient underwent nasal swab rapid test and the result was negative and heart rate and the result was elevated. The clinical outcome of the events dizzy, headache (small), lots of anxiety and elevated heart rate were not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Rash erythematous, Rash macular, Tenderness
Clinical narrative: Red rash over chest and torso (not hives, not a pinprick rash); Splotchy rash; Rash has a tender sensation similar to a sunburn.; This is a spontaneous report from a contactable consumer, the patient. A 19-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 13Apr2021 (at the age of 19-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included ethinylestradiol, ferrous fumarate, norethisterone acetate (LO LOESTRIN FE) from an unknown date for an unspecified indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955) via an unspecified route of administration in the left arm on 23Mar2021 (at the age of 19-years-old) as a single dose for COVID-19 immunisation. On 14Apr2021 over 24 hours after receiving the second dose, the patient developed a red rash over chest and torso (not hives, not a pinprick rash). The rash was not raised and was a splotchy rash. The rash was not painful or itchy but had a tender sensation similar to a sunburn. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of events red rash over chest and torso (not hives, not a pinprick rash), splotchy rash and rash had a tender sensation similar to a sunburn was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Joint stiffness, Nausea
Clinical narrative: Nausea; Joint pain; Joint tightness; Clinical flare up; Extreme fatigue; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 13Apr2021 at 09:15 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included rheumatoid arthritis. Concomitant medications included methotrexate (MANUFACTURER UNKNOWN), levocabastine hydrochloride (ZYRTEC), folic acid (MANUFACTURER UNKNOWN), ascorbic acid, herbal nos, levoglutamide, lysine, magnesium, manganese, retinol, riboflavin, selenium, tocopherol, zinc (AIRBORNE) and sambucus nigra fruit (ELDERBERRY) taken for unknown indication on unknown date, unknown if ongoing. No known allergies were reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 23Mar2021 at 09:30 (at the age of 57-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 at 15:00 the patient experienced nausea, joint pain and tightness similar to an RA flare up and extreme fatigue. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the adverse events nausea, joint pain and tightness similar to an RA flare up and extreme fatigue. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events nausea, joint pain and tightness similar to an RA flare up and extreme fatigue was recovered on unspecified date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Pain in extremity
Clinical narrative: hand has been going numb even when the arm is straight; Injection arm obviously has pain; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EWOK3) via an unspecified route of administration in the arm right on 13Apr2021 at 18:00(at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive any medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EPTJ34) via an unspecified route of administration in the  right arm on 10Mar2021 at 13:00(at the age of 37-year-old) as a single dose for COVID-19 immunisation. The patient had no allergies to her knowledge. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 21:00, the patient's injection arm had pain, no redness/swelling and that hand went numb even when the arm was straight. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the events injection arm pain and hand went numb was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Rash pruritic
Clinical narrative: Rash on left side of face, neck and ear. Very itchy; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06Apr2021 at 14:00 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were reported as none. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously took azithromycin (Zpack) and experienced drug allergy. On 13Apr2021, the patient experienced rash on left side of face, neck and ear and very itchy. The event resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the event rash pruritic was unknown.   No follow-up attempts are needed; information about lot number cannot be obtained.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Hyperhidrosis, Malaise, Nausea, Pyrexia
Clinical narrative: Fell asleep and woke up at 4am sweaty with all side effects gone, general malaise continues due to lack of sleep.; general malaise continues due to lack of sleep.; fever and chills along with extreme nausea; fever and chills along with extreme nausea; fever and chills along with extreme nausea; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 14Apr2021 at 09:00 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history and no known allergies to medication, food or other products. Concomitant medications included spironolactone (MANUFACTURER UNKNOWN) and sertraline hydrochloride (ZOLOFT) and birth control (MANUFACTURER UNKNOWN); all for unknown indications from unknown dates and unknown if ongoing.  The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 24Mar2021 at 17:00 (at the age of 26-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine.  On 14Apr2021, around 23:00 on the day of the second shot the patient had a fever and chills along with extreme nausea. The patient fell asleep and woke up at 04:00 on 15Apr2021 and was sweaty with all side effects gone, general malaise continued due to lack of sleep. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events fever and chills along with extreme nausea was recovered on 15Apr2021 and of the events sweaty and general malaise due to lack of sleep was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Hypoaesthesia, Paraesthesia
Clinical narrative: Numbness right side of face; Dizziness; Numbness/tingling right side of face.; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 14Apr2021 at 14:15 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included sjogren's, degenerative disc disease and raynauds, fibro. Patient had no known allergies. Concomitant medications included gabapentin (MANUFACTURER UNKNOWN) 300 mg, duloxetine hydrochloride (DULOXETINE DR) 60 mg, trazodone (MANUFACTURER UNKNOWN) 100 mg all from an unknown date from an unspecified indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 15:00, the patient experienced numbness/tingling right side of face, dizziness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events numbness/tingling right side of face, dizziness was not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Feeling abnormal
Clinical narrative: Foggy headed for the next day; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 23Mar2021 at 16:45 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Other medical history was reported as none. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included minerals nos, vitamins nos (CENTRUM MULTIVITAMIN) from an unknown date for an unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Mar2021 at 08:00, on the next day of vaccination, the patient felt foggy headed. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event foggy headed was resolved on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Vaccination site pain
Clinical narrative: Injection site soreness; Body aches; Fever; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EN6204) via an unspecified route of administration in the right arm on 13Apr2021 at 15:00 (at the age of 46-year-old) as a single dose for COVID-19 immunisation. Medical history included birth control. Concomitant medications included cetirizine hydrochloride (ZYRTEC), birth control pill (MANUFACTURER UNKNOWN), naproxen sodium (ALEVE) for an unknown indication and from an unknown date. The patient had no known allergies to medications, food or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EP7534) via an unspecified route of administration in the right arm on 22Mar2021 at 10:30 (at the age of 46-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 06:00 after the second shot the patient had injection site soreness, body aches and fever that started about 15 hours of the shot. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of injection site soreness, body aches and fever were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.